First Horizon Corp Makes New $653,000 Investment in IQVIA Holdings Inc. $IQV

First Horizon Corp purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,440 shares of the medical research company’s stock, valued at approximately $653,000.

Several other large investors have also recently modified their holdings of the company. Alliancebernstein L.P. boosted its stake in IQVIA by 0.6% in the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock valued at $560,379,000 after acquiring an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of IQVIA during the 2nd quarter valued at $515,772,000. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after purchasing an additional 581,157 shares in the last quarter. Nordea Investment Management AB grew its stake in IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the last quarter. Finally, Lazard Asset Management LLC increased its position in IQVIA by 6.1% during the 2nd quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock valued at $294,145,000 after buying an additional 107,500 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE IQV opened at $241.95 on Wednesday. The company has a 50 day simple moving average of $225.53 and a two-hundred day simple moving average of $201.95. The stock has a market cap of $41.20 billion, a price-to-earnings ratio of 33.19, a PEG ratio of 2.45 and a beta of 1.36. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter last year, the company posted $2.84 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Stifel Nicolaus raised their price target on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. UBS Group lifted their target price on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and boosted their target price for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Citigroup raised their price target on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Finally, Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $249.19.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.